Table 2.
Clinical Characteristics by Random Assignment to MBSR(BC) or UC
| Characteristic | No. (%) | P | ||
|---|---|---|---|---|
| All Patients (N = 322) | UC (n = 155) | MBSR(BC) (n = 167) | ||
| Days since cancer treatment at baseline | .34 | |||
| Mean | 231 | 221 | 241 | |
| SD | 180 | 176 | 185 | |
| Stage of disease | .55* | |||
| 0 | 12.4 (40) | 12.3 (19) | 12.6 (21) | |
| I | 33.8 (109) | 36.1 (56) | 31.7 (53) | |
| II | 35.7 (115) | 34.8 (54) | 36.5 (61) | |
| III | 18.0 (58) | 16.8 (26) | 19.2 (32) | |
| Type of surgery | .62 | |||
| Lumpectomy | 46.6 (150) | 45.2 (70) | 47.9 (80) | |
| Mastectomy | 53.4 (172) | 54.8 (85) | 52.1 (87) | |
| Type of treatment received | .83 | |||
| Chemotherapy | 13.0 (42) | 14.8 (23) | 11.4 (19) | |
| Radiotherapy | 29.2 (94) | 28.4 (44) | 29.9 (50) | |
| Chemotherapy and radiotherapy | 35.7 (115) | 35.5 (55) | 35.9 (60) | |
| No chemotherapy or radiotherapy | 22.1 (71) | 21.3 (33) | 22.8 (38) | |
| Endocrine treatment | 55.9 (180) | 51.6 (80) | 59.9 (100) | .14 |
| Anastrozole | 17.7 (57) | 16.1 (25) | 19.2 (32) | .48 |
| Letrozole | 13.4 (43) | 10.3 (16) | 16.2 (27) | .12 |
| Levothyroxine | 12.1 (39) | 12.6 (21) | 11.6 (18) | .79 |
| Tamoxifen | 16.1 (52) | 15.5 (24) | 16.8 (28) | .76 |
| Other | 1.9 (6) | 1.8 (3) | 1.9 (3) | .93 |
| Multiple | 7.5 (24) | 7.1 (11) | 7.8 (13) | .81 |
| Pain medication | 24 (77) | 25 (38) | 23 (39) | .81 |
| Anxiolytic medication | 14 (45) | 10 (15) | 18 (30) | .03 |
| Antidepressant medication | 12 (38) | 9 (14) | 14 (24) | .14 |
Abbreviations: MBSR(BC), Mindfulness-Based Stress Reduction for Breast Cancer; SD, standard deviation; UC, usual care.
*
P value for linear trend.